We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.06 | 2.80% | 2.20 | 2.10 | 2.20 | 2.20 | 2.19 | 2.19 | 604,698 | 13:54:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.93 | 7.33M |
TIDMIMM
RNS Number : 9464F
Immupharma PLC
20 November 2020
20 November 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
FDA confirms 4 December 2020 for Type 'A' meeting to discuss guidance on forthcoming international Phase 3 trial of Lupuzor(TM) in Lupus patients
ImmuPharma PLC (LSE:IMM) (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, announces an update on the announcement issued on 10 November 2020, in respect to the new optimised international Phase 3 trial of Lupuzor(TM) in systemic lupus erythematosus ("SLE"), a potentially life-threatening auto-immune disease.
The US Food & Drug Administration ("FDA") has now confirmed the date of 4 December 2020 for a Type 'A' Meeting Request, with Avion Pharmaceuticals ("Avion"), ImmuPharma's licensing partner for Lupuzor(TM).
As part of the Type 'A' Meeting, Avion has asked the FDA for guidance on the following:
-- Key aspects of the study design, clinical end points and approval process for Lupuzor(TM); and
-- Consideration by the FDA for a conditional approval of Lupuzor(TM), whilst the Phase 3 trial is underway.
ImmuPharma will provide an update as soon as Avion has met with the FDA and notified ImmuPharma of the outcome.
Commenting on the announcement, Dimitri Dimitriou, CEO of ImmuPharma said :
"ImmuPharma and Avion are delighted that the FDA are expediting the Type 'A' Meeting for early December 2020. We look forward to providing a further update to the market following confirmation from Avion of the FDA's guidance post this meeting."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact: ImmuPharma PLC ( www.immupharma.com ) Tim McCarthy, Chairman + 44 (0) 207 152 4080 Dimitri Dimitriou, Chief Executive Officer Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550 Patrick Claridge John Howes Bob Pountney +44 (0) 203 815 8880 SI Capital (Joint Broker) Nick Emerson +44 (0) 1483 413500 4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60 Jean-Charles Snoy Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34 Erik De Clippel Backstage Communication Olivier Duquaine +32 (0) 477 504 784 Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
About Avion Pharmaceuticals LLC
Avion Pharmaceuticals, LLC, is a specialty pharmaceutical company formed to develop, acquire and market a portfolio of innovative pharmaceutical products in the Women's Health and other therapeutic categories aligned with its mission to improve the quality of patient lives. Avion Pharmaceuticals focuses on identifying opportunities to develop, acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfil unmet medical needs. For more information, visit www.avionrx.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCKKCBDDBDBPDD
(END) Dow Jones Newswires
November 20, 2020 02:00 ET (07:00 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions